Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose Of Review: Apolipoprotein C-III (ApoC-III) plays a pivotal role in triglyceride (TG) metabolism by inhibiting lipoprotein lipase and hepatic clearance of TG-rich lipoproteins, contributing to hypertriglyceridaemia and elevated cardiovascular risk, as well as a high risk of acute pancreatitis. This review aims to summarize current evidence on ApoC-III inhibition strategies.

Recent Findings: Current treatments targeting Apo C-III include two antisense oligonucleotides (ASOs) (volanesorsen and olezarsen), and a small interfering RNA (siRNA) (plozasiran). Volanesorsen, a second-generation ASO, has shown effectiveness in reducing TG and preventing acute pancreatitis, especially in patients with familial chylomicronemia syndrome (FCS). However, its use is limited by the risk of thrombocytopenia, likely related to its chemical structure rather than ApoC-III inhibition itself. Olezarsen, a third-generation ASO with GalNAc conjugation for targeted liver delivery, offers an improved safety profile and strong efficacy in lowering TG and atherogenic lipoproteins levels, making it a promising candidate for a broader clinical use. Plozasiran, a GalNAc-conjugated siRNA, has shown robust and sustained TG reductions with a favorable safety profile, and early data suggest it may also reduce acute pancreatitis risk. ApoC-III inhibition represents an innovative and effective approach in managing hypertriglyceridaemia and its complications. Further outcome-driven trials are essential to define its role in cardiovascular risk reduction.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11883-025-01315-wDOI Listing

Publication Analysis

Top Keywords

acute pancreatitis
12
apoc-iii inhibition
12
cardiovascular risk
8
safety profile
8
apoc-iii
5
risk
5
apoc-iii therapeutic
4
therapeutic target
4
target primetime
4
primetime clinical
4

Similar Publications

Background: Tacrolimus is a commonly used immunosuppressant with well-defined side effects, including hypertriglyceridemia and hyperglycaemia. However, acute pancreatitis is still not widely recognized as an adverse event related to tacrolimus.

Case Presentation: A 60-year-old male was admitted to the intensive care unit with symptoms and signs of acute pancreatitis.

View Article and Find Full Text PDF

A rare case of duodenojejunal intussusception causing biliary obstruction during pregnancy.

J Surg Case Rep

September 2025

Department of Radiology, Ibn Sina University Hospital Center, Avenue Ibn Rochd, Agdal District, Rabat 10000, Rabat-Salé-Kénitra Region, Morocco.

Intussusception is an uncommon cause of intestinal obstruction in adults and rarely encountered during pregnancy. Duodenal intussusception is particularly rare due to the fixed position of the duodenum. We report a unique case of duodenojejunal intussusception in a pregnant woman at 28 weeks of gestation, who presented with symptoms mimicking acute pancreatitis complicated by biliary tract obstruction.

View Article and Find Full Text PDF

Background: Current scoring systems for hypertriglyceridaemia-induced acute pancreatitis (HTG-AP) severity are few and lack reliability. The present work focused on screening predicting factors for HTG-SAP, then constructing and validating the visualization model of HTG-AP severity by combining relevant metabolic indexes.

Methods: Between January 2020 and December 2024, retrospective clinical information for HTG-AP inpatients from Weifang People's Hospital was examined.

View Article and Find Full Text PDF

Background: Severe acute pancreatitis (SAP) is a life-threatening condition requiring early risk stratification. While the Bedside Index for Severity in Acute Pancreatitis (BISAP) is widely used, its reliance on complex parameters limits its applicability in resource-constrained settings. This study introduces a decision tree model based on Classification and Regression Tree (CART) analysis, utilizing Neutrophil-to-Lymphocyte Ratio (NLR) and C-reactive Protein (CRP), as a simpler alternative for early SAP prediction.

View Article and Find Full Text PDF

Prognostic value of multiparameter [Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers for patients with advanced pancreatic cancer.

Eur J Nucl Med Mol Imaging

September 2025

Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yang Pu District, Shanghai, 200433, China.

Purpose: In this retrospective study, whether [Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers can predict the progression-free survival (PFS) and overall survival (OS) of patients with advanced pancreatic cancer was investigated.

Methods: Fifty-one patients who underwent [Ga]Ga-DOTA-FAPI-04 PET/MR scans before first-line chemotherapy were recruited. Imaging biomarkers, including the maximum tumor diameter, minimum apparent diffusion coefficient (ADC), maximum and mean standardized uptake values (SUV and SUV), fibroblast activation protein- (FAP-) positive tumor volume (FTV and W-FTV) and total lesion FAP expression (TLF and W-TLF), were recorded for primary and whole-body tumors.

View Article and Find Full Text PDF